Coronary Stents Market Size & Growth Forecast 2027–2036, By Segments (End Use, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Coronary Stents Market size was more than USD 8.8 billion in 2026 and is set to grow at a 2.47% CAGR between 2027 and 2036, exceeding USD 11.23 billion by 2036. The industry revenue for 2027 is assessed at USD 8.98 billion.

• Base Year Value (2026): USD 8.8 billion
• CAGR (2027-2036): 2.47%
• Forecast Year Value (2036): USD 11.23 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Coronary Stents Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America holds a 46.22% share, supported by advanced interventional cardiology infrastructure, widespread catheterization labs, and consistently high volumes of stent-based procedures across established healthcare systems.
  • Asia Pacific is expanding at a 2.96% CAGR, driven by rising access to minimally invasive cardiac care, expanding hospital capabilities, and increasing adoption of stent procedures in standard cardiovascular treatment pathways.

• Segment Momentum:

  • Drug Eluting Stents accounted for a 78.19% share in 2026, supported by broad clinical adoption, physician familiarity, and routine use within established coronary intervention protocols.
  • Outpatient Facilities are growing fastest because providers increasingly favor efficient treatment settings that support high patient throughput, shorter stays, and lower procedural resource requirements.

• Market Expansion Drivers:

  • Rising prevalence of coronary artery disease increasing demand for minimally invasive cardiac interventions.
  • Advancements in bioresorbable and drug-eluting stent technologies improving clinical adoption rates.
  • Expanding outpatient cardiac care infrastructure supporting broader stent-based treatment accessibility.

• Leading Market Participants:

  Key companies in the coronary stents market include Abbott Laboratories (USA), Medtronic plc (Ireland), Boston Scientific Corporation (USA), Terumo Corporation (Japan), BIOTRONIK SE & Co. KG (Germany), B. Braun SE (Germany), MicroPort Scientific Corporation (China), Cook Medical LLC (USA), SMT SA (Switzerland).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 8.8 billion
  • 2027 Estimated Market Size: USD 8.98 billion.
  • Projected Market Size: USD 11.23 billion by 2036
  • Growth Forecasts: 2.47% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Outpatient Facilities (End Use) | Drug Eluting Stents (Product)
  • Emerging Opportunity Segment: Outpatient Facilities (End Use) | Bioresorbable Vascular Scaffolds (BVS)/Bioresorbable Coronary Stents (Product)

Market Growth Drivers and Industry Trends

Rising prevalence of coronary artery disease increasing demand for minimally invasive cardiac interventions

The increasing burden of coronary artery disease will drive the coronary stents market as more patients require interventions to restore blood flow through narrowed or obstructed coronary arteries. Percutaneous coronary intervention provides a less invasive treatment approach than open surgical procedures, supporting the use of stents to maintain vessel patency following arterial opening. Growing clinical demand for minimally invasive cardiac care is also encouraging healthcare providers to strengthen interventional cardiology capabilities, with stent-based procedures remaining an important treatment option for appropriate patients with coronary artery blockages.

Advancements in bioresorbable and drug-eluting stent technologies improving clinical adoption rates

Technological progress in stent design and drug-delivery capabilities is strengthening the coronary stents market by addressing important considerations surrounding restenosis, vessel healing, and long-term treatment outcomes. Drug-eluting stents can release therapeutic agents at the treatment site to reduce excessive tissue growth, while bioresorbable technologies are being developed to provide temporary vessel support before gradually breaking down. Continued innovation in materials, coatings, delivery systems, and stent architecture is providing clinicians with more specialized treatment options for different patient and lesion characteristics.

Expanding outpatient cardiac care infrastructure supporting broader stent-based treatment accessibility

The expansion of outpatient cardiac care infrastructure will boost the coronary stents market by making interventional cardiac procedures more accessible across a wider range of healthcare settings. Development of specialized cardiac centers, catheterization facilities, and ambulatory treatment capabilities is improving the availability of minimally invasive coronary interventions outside traditional hospital environments. Greater procedural capacity, supported by improvements in imaging, patient monitoring, and post-procedure care, allows healthcare providers to manage suitable patients through streamlined treatment pathways while maintaining access to stent-based interventions.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of coronary artery disease increasing demand for minimally invasive cardiac interventions	1.80%	High	North America, Asia Pacific	High	Near Term
Advancements in bioresorbable and drug-eluting stent technologies improving clinical adoption rates	1.60%	High	North America, Europe	Medium	Mid Term
Expanding outpatient cardiac care infrastructure supporting broader stent-based treatment accessibility	1.30%	Moderate	Asia Pacific, Latin America	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

In the coronary stents market, North America held a 46.22% share in 2026, reflecting its advanced cardiovascular care infrastructure, established interventional cardiology capabilities, and strong adoption of innovative medical technologies. The region benefits from sophisticated catheterization facilities and extensive clinical expertise in percutaneous coronary interventions, while increasing emphasis on minimally invasive treatment supports continued demand for coronary stent technologies. Ongoing improvements in stent design, procedural techniques, and patient-centered cardiovascular care further strengthen the region’s market position.

Asia Pacific is the fastest-growing regional market, supported by expanding cardiovascular healthcare infrastructure, rising awareness of heart disease, and improving access to interventional treatment. Healthcare systems are increasingly investing in specialized cardiac facilities and advanced diagnostic and therapeutic technologies to address growing demand for cardiovascular care. Broader adoption of minimally invasive procedures, expanding clinical capabilities, and increasing healthcare expenditure are creating significant opportunities for coronary stent adoption across the region.

Key Country Insights

United States

Advanced Cardiac Intervention

In the U.S., coronary stent usage is strongly tied to advanced interventional cardiology practices and rapid adoption of next-generation drug-eluting technologies. Cardiology centers prioritize devices that support complex lesion treatment, procedural safety, and reduced post-operative complications in high-volume cardiac care settings.

Japan

High-Risk Patient Management

Japan focuses on coronary stents used in managing complex cardiovascular cases and aging patient populations requiring precision intervention. In Japan, healthcare providers prioritize device flexibility, safety profiles, and compatibility with highly controlled clinical procedures.

South Korea

Technology-Driven Cardiology Care

South Korea increasingly adopts advanced coronary stents within digitally enabled cardiac catheterization laboratories. In South Korea, hospitals emphasize procedural efficiency, device innovation, and integration with modern imaging and diagnostic support systems in cardiovascular care.

Germany

Evidence-Based Cardiology Systems

Germany emphasizes coronary stents supported by strong clinical validation and structured cardiovascular treatment protocols. In Germany, hospitals prioritize long-term patient outcomes, device reliability, and integration with established interventional cardiology workflows across specialized cardiac centers.

France

Structured Cardiac Treatment Pathways

France prioritizes coronary stents within standardized cardiovascular treatment pathways across public healthcare facilities. In France, clinical decisions focus on patient safety, regulatory compliance, and consistent use of well-established interventional cardiology devices.

Italy

Interventional Cardiology Expansion

Italy continues to expand interventional cardiology capacity, supporting sustained use of coronary stents across regional hospital networks. In Italy, healthcare providers focus on balancing procedural accessibility with device reliability in routine and complex cardiac interventions.

Segment Leadership and Growth Trends

 

End Use Segment Analysis: Outpatient Facilities (Largest & Fastest-Growing Segment)

Outpatient facilities segment accounted for the largest share of the coronary stents market, reaching 59.96% in 2026, while also representing the fastest-growing end-use category. Its strong position is supported by the increasing shift toward minimally invasive cardiac interventions that can be performed without prolonged hospitalization, helping healthcare providers improve resource utilization and patient convenience. Advances in stent-based procedures, improved clinical protocols, and growing preference for shorter recovery periods are further reinforcing demand in outpatient settings.

Product Segment Analysis: Drug Eluting Stents (Largest Segment) vs Bioresorbable Vascular Scaffolds (BVS)/Bioresorbable Coronary Stents (Fastest-Growing Segment)

Drug eluting stents dominated the coronary stents market with a 78.19% share in 2026, supported by their established role in reducing the risk of restenosis through controlled drug release at the treatment site. Their broad clinical acceptance, proven performance, and continued use in percutaneous coronary interventions have sustained their leading position as healthcare providers prioritize effective vessel support and long-term treatment outcomes.

Bioresorbable vascular scaffolds (BVS)/Bioresorbable coronary stents are advancing at the fastest pace as innovation in coronary intervention increasingly focuses on temporary vessel support followed by natural resorption. The potential to reduce the long-term presence of permanent implant material, together with ongoing improvements in scaffold design and material performance, is strengthening interest in these technologies for selected coronary procedures.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
End Use	Inpatient Facilities, Outpatient Facilities	Outpatient Facilities	Outpatient Facilities
Product	Bare Metal Stents, Drug Eluting Stents, Bioresorbable Vascular Scaffolds (BVS)/Bioresorbable Coronary Stents	Drug Eluting Stents	Bioresorbable Vascular Scaffolds (BVS)/Bioresorbable Coronary Stents

Competitive Landscape and Market Positioning

Key companies in the coronary stents market:

1. Abbott Laboratories (USA)

2. Medtronic plc (Ireland)

3. Boston Scientific Corporation (USA)

4. Terumo Corporation (Japan)

5. BIOTRONIK SE & Co. KG (Germany)

6. B. Braun SE (Germany)

7. MicroPort Scientific Corporation (China)

8. Cook Medical LLC (USA)

9. SMT SA (Switzerland)

The coronary stents market remains highly innovation-driven, supported by increasing focus on advanced cardiovascular treatment solutions. Industry participants are developing next-generation stents with improved drug-eluting capabilities, enhanced flexibility, and better long-term patient outcomes. Expanding clinical research efforts and advancements in minimally invasive cardiac procedures are also strengthening competition and accelerating technological progress in the market.

Industry Development/News

Company Name	Date	Key Development
Nissha	Jun-26	Nissha acquired a 60% stake in USM Healthcare Medical Devices Factory JSC in Vietnam, marking a strategic expansion into Southeast Asian cardiovascular stent manufacturing. This move enhances the company's regional production and distribution footprint, positioning it to better serve the growing interventional cardiology market in Asia through increased operational capacity and local manufacturing integration.
Artivion	Apr-26	Artivion secured FDA pre-market approval for its aortic stent graft system, enabling immediate commercialization of the technology. The approval also triggered a buyout option for Endospan, a move that reinforces Artivion’s competitive positioning in advanced vascular and cardiac intervention technologies while accelerating the integration of specialized stent graft solutions into its broader clinical portfolio.
National Pharmaceutical Pricing Authority	Apr-26	India’s NPPA revised price caps for coronary stents, setting drug-eluting stents at ₹39,186 and bare-metal stents at ₹10,762. This regulatory intervention significantly alters the pricing landscape for manufacturers operating in the Indian market, impacting margins and necessitating strategic adjustments to distribution and commercial models to maintain access and compliance within this high-growth clinical segment.
Abbott	Mar-26	Abbott launched its XIENCE Skypoint drug-eluting stent in India, expanding its portfolio of advanced coronary intervention technologies. This rollout supports the company’s objective to strengthen its global leadership in interventional cardiology by providing next-generation stent solutions to a high-growth market, directly addressing the demand for enhanced efficacy and procedural safety in complex coronary care.
Uppsala University	Sep-24	Researchers at Uppsala University developed a flexible stent designed to reduce complications in coronary artery surgery. The device's efficacy was evaluated against the conventional Resolute Onyx stent in the 2,400-patient Infinity-Swedeheart study. This innovation represents a significant technological advancement with potential to improve patient outcomes and define new performance benchmarks for future stent design and clinical application.
Silk Road Medical	Mar-24	Silk Road Medical launched the Tapered ENROUTE Transcarotid Stent System in the U.S. market. The introduction of these tapered configurations expands the company’s existing portfolio of carotid solutions, providing physicians with specialized tools tailored to diverse patient anatomies and strengthening the company's competitive position within the niche segment of transcarotid interventions.